Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 7/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | ATM | Q13315 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cgs-21680 SCHEMBL12648395 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL13285993 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL14397691 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL3730487 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL2318561 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL724685 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL24178317 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL19807521 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL26629876 | 0.99 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E | |
| Cgs-21680 SCHEMBL29381841 | 0.99 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 720 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262274-A1 | Designed Biosensors for Enhanced T Cell Therapy | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2025-08-21 | — | — | US | claimed |
| CN-119969964-A | Research method for influence on TBI post-impulse behavior | 重庆医科大学 | 2025-05-13 | — | — | CN | claimed |
| CN-119838153-A | Method for regulating and controlling lymphatic system and application thereof | 温州医科大学附属眼视光医院 | 2025-04-18 | — | — | CN | claimed |
| EP-4526335-A1 | DESIGNED BIOSENSORS FOR ENHANCED T CELL THERAPY | Centre Hospitalier Universitaire Vaudois (CH) | 2025-03-26 | — | — | EP | claimed |
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-10-31 | — | — | US | claimed |
| CN-118813543-A | Multi-mode tracer three-reporter gene stem cell line, preparation method thereof, and brain tracer application and imaging system | 浙江大学 | 2024-10-22 | — | — | CN | claimed |
| WO-2024215814-A2 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING AGING | ANAND RENE (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024182811-A1 | COMPOSITIONS AND METHODS FOR TREATING UTERINE LEIOMYOMAS | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-09-06 | — | — | WO | claimed |
| WO-2024168320-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DEMENTIA | ANAND RENE (US) | 2024-08-15 | — | — | WO | claimed |
| US-11519008-B2 | Exosome delivery system | JOSLIN DIABETES CENTER (US) | 2022-12-06 | — | — | US | claimed |
| EP-4051715-A1 | DEGRADATION OF SURFACE PROTEINS USING BISPECIFIC BINDING AGENT | The Regents of the University of California (US) | 2022-09-07 | — | — | EP | claimed |
| CN-114867752-A | Degradation of surface proteins using bispecific binders | 加利福尼亚大学董事会 | 2022-08-05 | — | — | CN | claimed |
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-04-15 | — | — | US | claimed |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-04-18 | — | — | US | claimed |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY | 2018-12-06 | — | — | US | claimed |
| EP-3280414-A1 | ADENOSINE RECEPTOR MODULATORS FOR THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS | Oxford University Innovation Limited (GB) | 2018-02-14 | — | — | EP | claimed |
| WO-2017178820-A1 | ADENOSINE RECEPTOR MODULATORS FOR THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-10-19 | — | — | WO | claimed |
| WO-2016183217-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | YALE UNIVERSITY (US) | 2016-11-17 | — | — | WO | claimed |
| EP-0983768-A1 | MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Nippon Shinyaku Co., Ltd. (JP) | 2000-03-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358663-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | VASP, MYLK, EDNRB | ADORA2A 7/4885ADORA3 59/4885ADORA1 68/4885 |
| US-20210106605-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 4/4885 |
| US-20180344655-A1 | FUNCTIONALIZED POLYMERIC PARTICLES FOR TREATMENT OF GLIOMAS | PHLPP1, PHLPP2, PLAA | ADORA2A 10/4885ADORA3 32/4885ADORA1 39/4885 |
| US-20190111069-A1 | Adenosine Receptor Modulators for the Treatment of Circadian Rhythm Disorders | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.